NCT05769738

The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation

The Addition of Inhaled FUROsemide to Standard of Care in COPD Exacerbation: a Randomized Double Blinded Control Trial (FUROSCOPE Trial)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: American University of Beirut Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this randomized controlled trial is to determine the effect of adding inhaled furosemide to the known treatment of patient with Chronic obstructive pulmonary disease (COPD) exacerbation. It primarily aims at studying its effect on: 1. Relief of dyspnea sensation 2. Length of hospital stay Participants will be receiving the standard therapy of COPD exacerbation plus either inhaled furosemide or inhaled saline over 3 days. They will be asked to: * Perform spirometry * Fill in dyspnea score * Do arterial blood gases (ABGs)

Conditions

• Chronic Obstructive Pulmonary Disease Exacerbation
• COPD Exacerbation

Interventions

Type	Name	Description
DRUG	Furosemide	40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
DRUG	Normal saline	4ml of normal saline to be nebulized 3 times daily for 3 days

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2023-03-15
• Last updated: 2023-03-15